Biography
John is a biotechnology translational medicine consultant with a comprehensive and deep understanding of the development and application of pioneering molecular procedures to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests. John oversaw the translation of an early stage research Next Generation sequencing test to a US government reimbursed and now widely adopted Laboratory Developed CLIA-CAP test for transplanted kidney rejection. He advises commercial translation efforts at Stanford University (SPARK) and University of California in San Francisco (CATALYST).
Clinical Dx Showcase:
Molecular Stethoscope
Molecular Stethoscope is a seed-stage biotechnology company developing precision healthcare integrated solutions based on its proprietary circulating cell-free mRNA (cf-mRNA) technology platform. We are combining novel cf-mRNA technologies with next-generation sequencing, clinical information, and machine learning to dynamically monitor the health of patients with precision - without organ biopsies. In the near-term, we aspire to become the partner of choice for pharmaceutical companies looking to develop the right therapies, for the right patients, at the right time by deploying our cf-mRNA/information technology platform to increase our partners’ probability of technical success at all stages of their R&D process. Our long-term focus is to develop and commercialize a cf-mRNA/clinical information integrated solution for the early detection, diagnosis and therapy-response monitoring of chronic diseases in multiple organ systems within precision healthcare starting with the liver (e.g., Nonalcoholic Steatohepatitis - NASH) and the central nervous system (e.g., Alzheimer’s Disease and Multiple Sclerosis).
Cell-free mRNA: Realizing The Potential For Clinical Translation
This talk will focus on a novel clinical information technology, digital platform solution that Molecular Stethoscope is developing based on a powerful new analyte in peripheral blood: circulating cell-free mRNA. Human proof-of-concept studies in NASH, Transplant Oncology and Neurodegeneration will be presented, highlighting potential applications in clinical practice and in Pharmaceutical R&D to increase the probability of technical success.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
